LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Niraparib|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Pegfilgrastim|DRUG: Carboplatin
Sponsor: Wake Forest University Health Sciences
Collaborators: Tesaro, Inc.